2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 353-355
Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

834 Lymphodepletion promotes host inflammatory signaling to enhance CAR T cell therapy

Jack Kukulis, Saúl Alcántara2, Amelia Kung3, Caruna Jacob4, Miriam Y Kim, MD5
1 Washington University, Saint Louis, Missouri, United States
2 Washington University, Saint Louis, Missouri, United States
3 Washington University, Saint Louis, Missouri, United States
4 Washington University, Saint Louis, Missouri, United States
5 Washington University, Saint Louis, Missouri, United States

Lymphodepletion (LD) is required for effective chimeric antigen receptor (CAR) T cell therapy, as depletion of endogenous lymphocytes is known to enhance the efficacy of adoptively transferred T cells. Here we investigated whether alternative methods of LD could support the anti-tumor activity of CD19-targeting CAR T cells (CART19) using immunocompetent mouse models; by doing so we identified new mechanistic insights into how LD promotes CAR T cell function.

To establish the optimal interval between LD and CART19, C57BL/6 mice were given either no LD or cyclophosphamide (Cy) 250mg/kg on day -2, -6 or -10, followed by intravenous injection of 9523+19, a murine acute promyelocytic leukemia cell line engineered to express CD19, on day -1. All mice received CART19 on day 0. As expected, CART19 had no activity without LD, and these mice died of leukemia with a median survival of 22 days. In contrast, Cy given on day -2 enabled robust CART19 expansion, sustained B cell aplasia, and improved survival (median 41 days, p<0.0001). However, Cy given on day -6 or day -10 failed to support CART19 activity, as these groups showed no survival benefit as compared to no LD controls.

We next evaluated whether radiation could provide a more durable LD platform for CART19. A single dose of 6Gy total-body irradiation supported CART19 activity even when administered 15 days before CAR T cell infusion, improving survival as compared to no LD (median 40 vs 22 days; p=0.0016). However, 6Gy radiation caused significant pancytopenia, which is concerning as prolonged hematologic toxicity is a common side effect of CART19 therapy in human patients.

We proceeded to evaluate whether LD using lymphocyte targeting antibodies could support CART19 activity without increasing toxicity. A combination of antibodies (Ab) targeting T cells (Thy1), B cells (CD20), and NK cells (NK1.1) was given at doses selected to achieve more profound and prolonged lymphocyte depletion than Cy. Anti-Thy1.1 antibody was used to selectively deplete endogenous T cells in Thy1.1+ mice without affecting Thy1.2+ 9523+19 leukemia cells or Thy1.2+ CART19. Ab given on day -2 was able to support CART19 activity and overall survival was equivalent to day -2 Cy (median 31.5 vs 45 days, p=0.56). Notably, administration of Ab on day -6 or day -10 failed to support CART19 activity despite sustained lymphocyte depletion. These results suggest that elimination of endogenous lymphocytes is not the sole mechanism by which LD supports CAR T cells.

In addition to depletion of lymphocytes, all LD modalities induce varying degrees of host inflammation. We hypothesized that LD-mediated inflammatory activation of host immune cells may contribute to the efficacy of CART19. To test this, we evaluated CART19 activity in mice genetically deficient for MyD88, a key mediator of inflammatory signaling. Wild-type (WT) or MyD88 KO (KO) mice were given Cy and EZB-P6, a CD19+ B cell lymphoma, followed by treatment with CART19 derived from WT mice. Both WT and KO mice rapidly succumbed to lymphoma in the absence of treatment (median survival: 10 days). While CART19 improved the survival of KO mice, only WT mice exhibited long-term disease control (median 28 days vs undefined, p=0.0034). The survival of KO mice was also inferior to WT mice when CART19 was given after 6Gy radiation (median 39 days vs undefined, p=0.048), demonstrating that host MyD88-dependent inflammatory signaling contributes to CART19 efficacy in vivo.

Finally, we tested whether adding inflammatory stimuli could enhance CART19 activity in WT mice after LD. WT mice were given Ab on day -2 followed by 9523+19 on day -1, CART19 on day 0, and lipopolysaccharide (LPS) on day 1. Addition of LPS significantly increased CAR T cell expansion and overall survival compared with Ab alone (median undefined vs 36 days, p=0.012). Addition of LPS also improved CAR T cell expansion and overall survival in mice given Cy and a suboptimal dose of CART19 (median undefined vs 45 days, p=0.017).

In summary, we show that LD is required for CART19 activity in C57BL/6 mice, that its effects are partially dependent on host MyD88-mediated inflammatory activation, and that amplification of MyD88 signaling can further enhance CAR T cell activity. These results indicate that LD has a role beyond lymphocyte depletion in supporting CAR T cell therapy, and this can be exploited to improve therapeutic outcomes.

Miriam Y Kim, MD: No relevant conflicts of interest to declare.